PURPOSE: To develop an in vivo two-dimensional localized correlation spectroscopy technique with which to monitor the biochemistry of the human brain and the pathologic characteristics of diseases in a clinically applicable time, including ascertainment of appropriate postprocessing parameters with which to allow diagnostic and prognostic molecules to be measured, and to investigate how much of the chemical information, known to be available from malignant cultured cells, could be recorded in vivo from human brain. MATERIALS AND METHODS: The study was approved by the institutional review board and was compliant with HIPAA. With use of a 3.0-T clinical magnetic resonance (MR) unit and a 32-channel head coil, localized correlation spectroscopy was performed in six healthy control subjects and six patients with glioblastoma multiforme (GBM) with an acquisition time of 11 minutes. Two-dimensional spectra were processed and analyzed and peak volume ratios were tabulated. The data used were proved to be normally distributed by passing the Shapiro-Wilk normality test. The first row of the spectra was extracted to examine diagnostic features. The pathologic characteristics and grade of each GBM were determined after biopsy or surgery. Statistically significant differences were assessed by using a t test. RESULTS: The localized correlation spectroscopy method assigned biochemical species from the healthy human brain. The correlation spectra of GBM were of sufficiently high quality that many of the cross peaks, recorded previously from malignant cell models in vitro, were observed, demonstrating a statistically significant difference (P < .05) between the cross peak volumes measured for healthy subjects and those with GBM (which include lipid, alanine, N-acetylaspartate, γ-aminobutyric acid, glutamine and glutamate, glutathione, aspartate, lysine, threonine, total choline, glycerophosphorylcholine, myo-inositol, imidazole, uridine diphosphate glucose, isocitrate, lactate, and fucose). The first row of the spectra was found to contain diagnostic features. CONCLUSION: Localized correlation spectroscopy of the human brain at 3.0 T with use of a 32-channel head coil was performed in 11 minutes and provided information about neurotransmitters, metabolites, lipids, and macromolecules. The method was able to help differentiate healthy brain from the biochemical signature of GBM in vivo. This method may, in the future, reduce the need for biopsy and is now applicable for the study of selected neurologic diseases. RSNA, 2011
PURPOSE: To develop an in vivo two-dimensional localized correlation spectroscopy technique with which to monitor the biochemistry of the human brain and the pathologic characteristics of diseases in a clinically applicable time, including ascertainment of appropriate postprocessing parameters with which to allow diagnostic and prognostic molecules to be measured, and to investigate how much of the chemical information, known to be available from malignant cultured cells, could be recorded in vivo from human brain. MATERIALS AND METHODS: The study was approved by the institutional review board and was compliant with HIPAA. With use of a 3.0-T clinical magnetic resonance (MR) unit and a 32-channel head coil, localized correlation spectroscopy was performed in six healthy control subjects and six patients with glioblastoma multiforme (GBM) with an acquisition time of 11 minutes. Two-dimensional spectra were processed and analyzed and peak volume ratios were tabulated. The data used were proved to be normally distributed by passing the Shapiro-Wilk normality test. The first row of the spectra was extracted to examine diagnostic features. The pathologic characteristics and grade of each GBM were determined after biopsy or surgery. Statistically significant differences were assessed by using a t test. RESULTS: The localized correlation spectroscopy method assigned biochemical species from the healthy human brain. The correlation spectra of GBM were of sufficiently high quality that many of the cross peaks, recorded previously from malignant cell models in vitro, were observed, demonstrating a statistically significant difference (P < .05) between the cross peak volumes measured for healthy subjects and those with GBM (which include lipid, alanine, N-acetylaspartate, γ-aminobutyric acid, glutamine and glutamate, glutathione, aspartate, lysine, threonine, total choline, glycerophosphorylcholine, myo-inositol, imidazole, uridine diphosphate glucose, isocitrate, lactate, and fucose). The first row of the spectra was found to contain diagnostic features. CONCLUSION: Localized correlation spectroscopy of the human brain at 3.0 T with use of a 32-channel head coil was performed in 11 minutes and provided information about neurotransmitters, metabolites, lipids, and macromolecules. The method was able to help differentiate healthy brain from the biochemical signature of GBM in vivo. This method may, in the future, reduce the need for biopsy and is now applicable for the study of selected neurologic diseases. RSNA, 2011
Authors: M A Thomas; K Yue; N Binesh; P Davanzo; A Kumar; B Siegel; M Frye; J Curran; R Lufkin; P Martin; B Guze Journal: Magn Reson Med Date: 2001-07 Impact factor: 4.668
Authors: Daniel Pretto Schunemann; Ivana Grivicich; Andréa Regner; Lisiane Freitas Leal; Daniela Romani de Araújo; Geraldo Pereira Jotz; Carlos Alexandre Fedrigo; Daniel Simon; Adriana Brondani da Rocha Journal: Pathol Oncol Res Date: 2009-12-08 Impact factor: 3.201
Authors: Simone Barbero; Rudy Bonavia; Adriana Bajetto; Carola Porcile; Paolo Pirani; Jean Louis Ravetti; Gian Luigi Zona; Renato Spaziante; Tullio Florio; Gennaro Schettini Journal: Cancer Res Date: 2003-04-15 Impact factor: 12.701
Authors: Inga Harting; Marius Hartmann; Gregor Jost; Clemens Sommer; Rezvan Ahmadi; Sabine Heiland; Klaus Sartor Journal: Neurosci Lett Date: 2003-05-22 Impact factor: 3.046
Authors: Ovidiu C Andronesi; Grace S Kim; Elizabeth Gerstner; Tracy Batchelor; Aria A Tzika; Valeria R Fantin; Matthew G Vander Heiden; A Gregory Sorensen Journal: Sci Transl Med Date: 2012-01-11 Impact factor: 17.956
Authors: Susan E Waisbren; Sanjay P Prabhu; Patricia Greenstein; Carter Petty; Donald Schomer; Vera Anastasoaie; Kalin Charette; Daniel Rodriguez; Sai Merugumala; Alexander P Lin Journal: JIMD Rep Date: 2016-09-28
Authors: Alexander P Lin; Saadallah Ramadan; Robert A Stern; Hayden C Box; Christopher J Nowinski; Brian D Ross; Carolyn E Mountford Journal: Alzheimers Res Ther Date: 2015-03-15 Impact factor: 6.982
Authors: Stephen J Price; Adam M H Young; William J Scotton; Jared Ching; Laila A Mohsen; Natalie R Boonzaier; Victoria C Lupson; John R Griffiths; Mary A McLean; Timothy J Larkin Journal: J Magn Reson Imaging Date: 2015-07-03 Impact factor: 4.813
Authors: Thomas Sc Ng; Alexander P Lin; Inga K Koerte; Ofer Pasternak; Huijun Liao; Sai Merugumala; Sylvain Bouix; Martha E Shenton Journal: Alzheimers Res Ther Date: 2014-02-24 Impact factor: 6.982
Authors: Gaurav Verma; Suyash Mohan; MacLean P Nasrallah; Steven Brem; John Y K Lee; Sanjeev Chawla; Sumei Wang; Rajakumar Nagarajan; M Albert Thomas; Harish Poptani Journal: J Transl Med Date: 2016-09-22 Impact factor: 5.531